Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
McKinsey
Argus Health
UBS
US Army
Accenture
Harvard Business School
Colorcon
Express Scripts

Generated: May 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,049,328

« Back to Dashboard

Which drugs does patent 7,049,328 protect, and when does it expire?

Patent 7,049,328 protects FERRIPROX and is included in two NDAs.

This patent has sixteen patent family members in fifteen countries.
Summary for Patent: 7,049,328
Title:Use for deferiprone
Abstract: A method of treating iron induced cardiac disease in a patient with iron overload, such as in thalassemia or the like comprising administering to the patient a therapeutically effective amount of deferiprone or a physiologically acceptable salt thereof sufficient to treat iron induced cardiac disease normally associated with iron overload.
Inventor(s): Spino; Michael (Pickering, CA), Piga; Antonio (Moncalieri, IT)
Assignee: Apotex Inc. (Weston, CA)
Application Number:10/311,814
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,049,328
Patent Claim Types:
see list of patent claims
Use; Delivery; Composition; Dosage form; Formulation;

Drugs Protected by US Patent 7,049,328

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Apopharma Inc FERRIPROX deferiprone SOLUTION;ORAL 208030-001 Sep 9, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial METHOD OF TREATING CHRONIC IRON OVERLOAD ➤ Try a Free Trial
Apopharma Inc FERRIPROX deferiprone TABLET;ORAL 021825-001 Oct 14, 2011 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial METHOD OF TREATING CHRONIC IRON OVERLOAD ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,049,328

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Canada2313270Jun 30, 2000
PCT Information
PCT FiledJune 28, 2001PCT Application Number:PCT/CA01/00956
PCT Publication Date:January 10, 2002PCT Publication Number: WO02/02114

International Family Members for US Patent 7,049,328

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 427107 ➤ Try a Free Trial
Australia 2001270402 ➤ Try a Free Trial
Australia 7040201 ➤ Try a Free Trial
Brazil 0112280 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
Healthtrust
Julphar
Johnson and Johnson
Cantor Fitzgerald
Farmers Insurance
Express Scripts
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.